Wuhan General Group (China), Inc. (WUHN)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0150 - Volume
145,989 - Avg. Volume
0 - Market Cap (intraday)
30,533 - Beta (5Y Monthly) 0.86
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others. Wuhan General Group (China), Inc. is headquartered in Pointe-Claire, Canada.
wuhn.org700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: WUHN
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: WUHN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: WUHN
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
0.04
Enterprise Value/EBITDA
0.96
Financial Highlights
Profitability and Income Statement
Profit Margin
-13.18%
Return on Assets (ttm)
-0.50%
Return on Equity (ttm)
-8.78%
Revenue (ttm)
80.38M
Net Income Avi to Common (ttm)
-10.61M
Diluted EPS (ttm)
-0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
18.79M
Total Debt/Equity (mrq)
110.68%
Levered Free Cash Flow (ttm)
-37.94M
Company Insights: WUHN
WUHN does not have Company Insights